Skip to main content

Leukemia & Bone Marrow Transplant

Protocols

Bone Marrow Transplant

BMTIVBUCY

Myeloablative conditioning therapy prior to autologous and allogeneic hematopoietic stem cell transplantation for myeloid malignancies using IV busulfan and cyclophosphamide


BMTLPDRIT

Pre-Emptive riTUXimab Therapy of Epstein-Barr Virus (EBV) Related Post-Transplant Lymphoproliferative Disease


BMTMM0301

Conditioning therapy for autologous stem cell transplant using high dose melphalan in the treatment of multiple myeloma


MYHDC

Single dose cyclophosphamide priming therapy for multiple myeloma prior to autologous stem cell transplant.

Top

Leukemia & Other Myeloid Neoplasms

ULKAMLAMTN

Maintenance Oral azaCITIDine for Acute Myeloid Leukemia


LKAMLAS

Therapy of Acute Myeloid Leukemia Using azaCITIDine and SORAfenib


ULKAMLAVEN

Therapy of Acute Myeloid Leukemia using azaCITIDine and Venetoclax


LKAMLCYT

Therapy of Acute Myeloid Leukemia Using Low dose Cytarabine


LKAMLDCYT

Therapy of Acute Myeloid Leukemia using DAUNOrubicin Liposomal-Cytarabine Liposomal


ULKAMLGIL

Therapy of Relapsed or Refractory FLT3+ Acute Myeloid Leukemia using Gilteritinib


LKAMLMIDO

Therapy of FLT3+ Acute Myeloid Leukemia Using Midostaurin in Combination with Induction and Consolidation Chemotherapy


LKANAG

Anagrelide as second-line treatment of thrombocytosis related to myeloproliferative disorders


LKATOATRA

First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)


LKATOP

First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin (All-Trans Retinoic Acid) and DAUNOrubicin


LKATOR

Induction and Consolidation Therapy of Relapsed Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin (All-Trans Retinoic Acid)


ULKBLIN

Treatment of Philadelphia Chromosome (Ph)-Positive or Ph-Negative Refractory or Relapsed Pre-B-Cell Acute Lymphoblastic Leukemia with Blinatumomab


LKCMLA

Treatment of Chronic Myeloid Leukemia using Asciminib


LKCMLB

Treatment of Chronic Myeloid Leukemia Using Bosutinib


LKCMLI

Therapy for Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Imatinib


LKCMLD

Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Dasatinib


LKCMLN

Treatment of Chronic Myeloid Leukemia Using Nilotinib


ULKCMLP

Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Ponatinib


LKGEMOZ

Treatment of Acute Myeloid Leukemia Using Gemtuzumab Ozogamicin with Induction and Consolidation Chemotherapy


ULKINOZ

Treatment of Relapsed or Refractory Pre-B Cell Acute Lymphoblastic Leukemia with Inotuzumab Ozogamicin


LKMDSA

Therapy of Myelodysplastic Syndrome using Azacitidine


ULKMDSDC

Therapy of Myelodysplastic Syndrome using Decitabine-Cedazuridine


LKMDSL

Therapy of Myelodysplastic Syndrome using Lenalidomide


ULKMFFED

Treatment of Symptomatic Myelofibrosis with Fedratinib


LKMFRUX

Treatment of Symptomatic Myelofibrosis with Ruxolitinib


ULKMRDBLIN

Treatment of Pre-B-Cell Acute Lymphoblastic Leukemia with Minimal Residual Disease using Blinatumomab


LKPCVRUX

Treatment of Polycythemia Vera with Ruxolitinib


LKPEGIFN

Peginterferon Alfa-2a Therapy of Chronic Myeloid Neoplasms and Hypereosinophilic Syndrome


LYCODOXMR

Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Cyclophosphamide, vinCRIstine, DOXOrubicin, Methotrexate, Leucovorin (CODOX-M) and riTUXimab

LYIVACR

Treatment of Burkitt’s Lymphoma and Leukemia (ALL-L3) with Ifosfamide, Mesna, Etoposide, Cytarabine (IVAC) and riTUXimab


Funding Algorithm

The funding algorithm provides information on what anti-cancer systemic therapy treatments are covered on the BC Cancer Benefit Drug List (formulary). It may not be a complete list of all treatment options that may be available and recommended by the treating physician.





Terms of use
The information contained in these documents is a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. 

Use of these documents is at your own risk and is subject to BC Cancer's terms of use.


Tab Heading
SOURCE: Leukemia & Bone Marrow Transplant ( )
Page printed: . Unofficial document if printed. Please refer to SOURCE for latest information.

Copyright © BC Cancer. All Rights Reserved.

    Copyright © 2024 Provincial Health Services Authority